Alexion-Synageva Deal Shows Lure of Rare-Disease Drugs -- 3rd Update
Use this screen to find high-growth businesses that have big ideas to keep competitors at bay.
With "massive" student debt loads receding in the rearview mirror, a young professional couple fires up their investment plan.
Health-care stocks are on a tear as demand slowly returns.
The five biotech ETFs have very different portfolios with markedly different performance.
While we remain bullish on the sector, health-care growth depends on the economy.
With two years of stellar returns behind us, our expectations for 2013 are more muted, but some opportunities persist.